Skip to main content

New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, November 30[th] 2020. During November 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

The total number of shares and votes in the Company has increased as a result of the board of directors’ resolution to approve Nice & Green S.A.’s request to convert a number of convertible notes into a total of 561,151 common shares in the Company, with an average conversion price of 10.69 SEK/share, in accordance with the terms and conditions of the above mentioned financing agreement. On November 6th 2020, the board of Moberg Pharma decided on a fully guaranteed rights issue. When the rights issue is completed, the Company intends to terminate the current convertible note agreement. In addition to this conversion in November, there are convertible notes outstanding of 6 MSEK that may be converted at a later point in time.

At the date of this press release, the total number of shares in Moberg Pharma amounts to 20,419,562. All shares are common shares. The total number of votes are 20,419,562. At the date of this press release, the Company holds 554,746 own common shares.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail:

Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail:

About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on November 30th 2020 at 8:00 am CET.

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate that they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).